Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB
Xiao Feng
Li Ying
Xu Weilai
You Liangshun
Yang Chunmei
Liu Hui
Qian Wenbin
· 2016
期刊名称：
Oncology Letters
2016 年
11 卷
1 期
摘要：
The aim of the present study was to evaluate the treatment outcome of homoharringtonine, cytarabine (AraC) and aclarubicin combination therapy as induction treatment for myelodysplastic syndromes-refractory anemia with excess blasts (MDS-RAEB). A total of 24 patients with MDS-RAEB who were aged between 18 and 66 years were treated with homoharringtonine, AraC and aclarubicin (HAA regimen). The HAA regimen consisted of homoharringtonine (2 mg/m
会员登录
